rimantadine has been researched along with Respiratory Syndrome, Acute, Severe in 2 studies
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015." | 1.43 | Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. ( Fry, AM; McKimm-Breschkin, JL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McKimm-Breschkin, JL | 1 |
| Fry, AM | 1 |
| Chen, F | 1 |
| Chan, KH | 1 |
| Jiang, Y | 1 |
| Kao, RY | 1 |
| Lu, HT | 1 |
| Fan, KW | 1 |
| Cheng, VC | 1 |
| Tsui, WH | 1 |
| Hung, IF | 1 |
| Lee, TS | 1 |
| Guan, Y | 1 |
| Peiris, JS | 1 |
| Yuen, KY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19[NCT04372628] | Phase 2 | 452 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of days without fever from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 16 |
| Placebo Control Group | 17 |
Number of days outside the hospital from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days outside the ICU from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of Days without oxygen Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days from enrollment to hospitalization (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 6 |
| Placebo Control Group | 7 |
Number of days from enrollment to resolution of COVID-19 symptoms (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 11 |
| Placebo Control Group | 11 |
Number of vasopressor-free days through Study Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days without ventilator use from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
2 other studies available for rimantadine and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Topics: Amantadine; Antibody-Dependent Enhancement; Antiviral Agents; Coronavirus Infections; Drug Resistanc | 2016 |
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.
Topics: Adult; Antiviral Agents; Cell Line; Chlorogenic Acid; Drug Synergism; Female; Flavonoids; Glycyrrhiz | 2004 |